CN102369277B - 肺组织模型 - Google Patents
肺组织模型 Download PDFInfo
- Publication number
- CN102369277B CN102369277B CN201080020612.7A CN201080020612A CN102369277B CN 102369277 B CN102369277 B CN 102369277B CN 201080020612 A CN201080020612 A CN 201080020612A CN 102369277 B CN102369277 B CN 102369277B
- Authority
- CN
- China
- Prior art keywords
- cell
- model
- culture
- tissue culture
- dimensional
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000004072 lung Anatomy 0.000 title claims abstract description 152
- 238000013334 tissue model Methods 0.000 title claims description 17
- 238000012360 testing method Methods 0.000 claims abstract description 77
- 230000002685 pulmonary effect Effects 0.000 claims abstract description 46
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 39
- 201000010099 disease Diseases 0.000 claims abstract description 38
- 239000003814 drug Substances 0.000 claims abstract description 35
- 239000002407 tissue scaffold Substances 0.000 claims abstract description 17
- 229940079593 drug Drugs 0.000 claims abstract description 11
- 208000019693 Lung disease Diseases 0.000 claims abstract description 9
- 238000012216 screening Methods 0.000 claims abstract description 9
- 230000000694 effects Effects 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims description 444
- 210000001519 tissue Anatomy 0.000 claims description 240
- 238000000034 method Methods 0.000 claims description 63
- 230000014509 gene expression Effects 0.000 claims description 58
- 239000003550 marker Substances 0.000 claims description 55
- 210000002919 epithelial cell Anatomy 0.000 claims description 52
- 239000000523 sample Substances 0.000 claims description 50
- 102000004127 Cytokines Human genes 0.000 claims description 36
- 108090000695 Cytokines Proteins 0.000 claims description 36
- 238000013459 approach Methods 0.000 claims description 35
- 230000008859 change Effects 0.000 claims description 32
- 230000004069 differentiation Effects 0.000 claims description 25
- 230000004054 inflammatory process Effects 0.000 claims description 25
- 239000013074 reference sample Substances 0.000 claims description 25
- 210000003725 endotheliocyte Anatomy 0.000 claims description 24
- 206010061218 Inflammation Diseases 0.000 claims description 23
- 238000012258 culturing Methods 0.000 claims description 23
- 239000000725 suspension Substances 0.000 claims description 23
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 21
- 230000008569 process Effects 0.000 claims description 21
- 210000002588 alveolar type II cell Anatomy 0.000 claims description 20
- 238000002156 mixing Methods 0.000 claims description 20
- 230000000770 proinflammatory effect Effects 0.000 claims description 19
- 108090000991 Aquaporin 3 Proteins 0.000 claims description 17
- 239000011159 matrix material Substances 0.000 claims description 17
- 102000004363 Aquaporin 3 Human genes 0.000 claims description 15
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 15
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 15
- 101000632178 Homo sapiens Homeobox protein Nkx-2.1 Proteins 0.000 claims description 14
- 101000845269 Homo sapiens Transcription termination factor 1 Proteins 0.000 claims description 14
- IMRYETFJNLKUHK-UHFFFAOYSA-N traseolide Chemical compound CC1=C(C(C)=O)C=C2C(C(C)C)C(C)C(C)(C)C2=C1 IMRYETFJNLKUHK-UHFFFAOYSA-N 0.000 claims description 13
- 210000002383 alveolar type I cell Anatomy 0.000 claims description 12
- 238000005469 granulation Methods 0.000 claims description 12
- 230000003179 granulation Effects 0.000 claims description 12
- 210000002744 extracellular matrix Anatomy 0.000 claims description 11
- 206010016654 Fibrosis Diseases 0.000 claims description 10
- 230000002776 aggregation Effects 0.000 claims description 10
- 238000004220 aggregation Methods 0.000 claims description 10
- 238000004458 analytical method Methods 0.000 claims description 10
- 230000004761 fibrosis Effects 0.000 claims description 10
- 230000002757 inflammatory effect Effects 0.000 claims description 10
- 102000000905 Cadherin Human genes 0.000 claims description 9
- 108050007957 Cadherin Proteins 0.000 claims description 9
- 230000001575 pathological effect Effects 0.000 claims description 9
- 101000975502 Homo sapiens Keratin, type II cytoskeletal 7 Proteins 0.000 claims description 8
- 102100023974 Keratin, type II cytoskeletal 7 Human genes 0.000 claims description 8
- 230000009286 beneficial effect Effects 0.000 claims description 8
- 238000004043 dyeing Methods 0.000 claims description 8
- 101000612671 Homo sapiens Pulmonary surfactant-associated protein C Proteins 0.000 claims description 7
- 108050000637 N-cadherin Proteins 0.000 claims description 7
- 102100040971 Pulmonary surfactant-associated protein C Human genes 0.000 claims description 7
- 239000012298 atmosphere Substances 0.000 claims description 7
- 230000009786 epithelial differentiation Effects 0.000 claims description 7
- 230000009466 transformation Effects 0.000 claims description 7
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 claims description 6
- 102100026236 Interleukin-8 Human genes 0.000 claims description 6
- 230000006378 damage Effects 0.000 claims description 5
- 101100310152 Homo sapiens SFTPA2 gene Proteins 0.000 claims description 4
- 101150047113 SFTPA1 gene Proteins 0.000 claims description 4
- 230000009471 action Effects 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 4
- 230000001172 regenerating effect Effects 0.000 claims description 4
- -1 IL1b Proteins 0.000 claims description 2
- 238000012423 maintenance Methods 0.000 claims description 2
- 231100000614 poison Toxicity 0.000 claims description 2
- 230000007096 poisonous effect Effects 0.000 claims description 2
- 102100027773 Pulmonary surfactant-associated protein A2 Human genes 0.000 claims 2
- 102100027893 Homeobox protein Nkx-2.1 Human genes 0.000 claims 1
- 238000011160 research Methods 0.000 abstract description 15
- 150000001875 compounds Chemical class 0.000 abstract description 7
- 238000003491 array Methods 0.000 abstract 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 51
- 238000004113 cell culture Methods 0.000 description 35
- 239000000203 mixture Substances 0.000 description 26
- 108090000623 proteins and genes Proteins 0.000 description 26
- 241000282414 Homo sapiens Species 0.000 description 23
- 108020004999 messenger RNA Proteins 0.000 description 22
- 239000000463 material Substances 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 20
- 230000003328 fibroblastic effect Effects 0.000 description 18
- 210000002950 fibroblast Anatomy 0.000 description 14
- 230000009977 dual effect Effects 0.000 description 13
- 210000004924 lung microvascular endothelial cell Anatomy 0.000 description 12
- 108010082117 matrigel Proteins 0.000 description 12
- 108090001005 Interleukin-6 Proteins 0.000 description 11
- 102100031079 Transcription termination factor 1 Human genes 0.000 description 11
- 239000000975 dye Substances 0.000 description 10
- 210000005265 lung cell Anatomy 0.000 description 10
- 238000009343 monoculture Methods 0.000 description 10
- 239000002516 radical scavenger Substances 0.000 description 10
- 102000010637 Aquaporins Human genes 0.000 description 9
- 108010063290 Aquaporins Proteins 0.000 description 9
- 208000037841 lung tumor Diseases 0.000 description 9
- 210000000130 stem cell Anatomy 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 8
- 210000003630 histaminocyte Anatomy 0.000 description 8
- 208000020816 lung neoplasm Diseases 0.000 description 8
- 102000026633 IL6 Human genes 0.000 description 7
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 7
- 102000013275 Somatomedins Human genes 0.000 description 7
- 210000001552 airway epithelial cell Anatomy 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 108700039887 Essential Genes Proteins 0.000 description 6
- 102000007615 Pulmonary Surfactant-Associated Protein A Human genes 0.000 description 6
- 108010007100 Pulmonary Surfactant-Associated Protein A Proteins 0.000 description 6
- 102100030060 Pulmonary surfactant-associated protein A1 Human genes 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- MURGITYSBWUQTI-UHFFFAOYSA-N fluorescin Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC=C(O)C=C2OC2=CC(O)=CC=C21 MURGITYSBWUQTI-UHFFFAOYSA-N 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 230000002269 spontaneous effect Effects 0.000 description 6
- 241000701161 unidentified adenovirus Species 0.000 description 6
- 108091006146 Channels Proteins 0.000 description 5
- 206010020880 Hypertrophy Diseases 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000008520 organization Effects 0.000 description 5
- 230000035479 physiological effects, processes and functions Effects 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 101710164994 50S ribosomal protein L13, chloroplastic Proteins 0.000 description 4
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 4
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 4
- 102000019034 Chemokines Human genes 0.000 description 4
- 108010012236 Chemokines Proteins 0.000 description 4
- 101710114425 Homeobox protein Nkx-2.1 Proteins 0.000 description 4
- 101000864780 Homo sapiens Pulmonary surfactant-associated protein A1 Proteins 0.000 description 4
- 101710088547 Thyroid transcription factor 1 Proteins 0.000 description 4
- 101710159262 Transcription termination factor 1 Proteins 0.000 description 4
- 229940112869 bone morphogenetic protein Drugs 0.000 description 4
- 230000008614 cellular interaction Effects 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 230000004068 intracellular signaling Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 108010036280 Aquaporin 4 Proteins 0.000 description 3
- 102100037276 Aquaporin-4 Human genes 0.000 description 3
- 102100025805 Cadherin-1 Human genes 0.000 description 3
- 101100264065 Danio rerio wnt5b gene Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 3
- 101000984015 Homo sapiens Cadherin-1 Proteins 0.000 description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 3
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 206010063036 Spinal cord oedema Diseases 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000000560 biocompatible material Substances 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000000739 chaotic effect Effects 0.000 description 3
- 238000004624 confocal microscopy Methods 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 229940126864 fibroblast growth factor Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000001476 gene delivery Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 210000004493 neutrocyte Anatomy 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000001338 self-assembly Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 208000037816 tissue injury Diseases 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 102000004392 Aquaporin 5 Human genes 0.000 description 2
- 108090000976 Aquaporin 5 Proteins 0.000 description 2
- 102100037332 Aquaporin-3 Human genes 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102400001368 Epidermal growth factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 2
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 102000013814 Wnt Human genes 0.000 description 2
- 108050003627 Wnt Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 210000000648 angioblast Anatomy 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000009087 cell motility Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 238000003255 drug test Methods 0.000 description 2
- 210000003989 endothelium vascular Anatomy 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 230000036449 good health Effects 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 235000015220 hamburgers Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 238000011206 morphological examination Methods 0.000 description 2
- 108060006184 phycobiliprotein Proteins 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 108700042226 ras Genes Proteins 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000005204 segregation Methods 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 238000013296 A/J mouse Methods 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000197194 Bulla Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000003858 Chymases Human genes 0.000 description 1
- 108090000227 Chymases Proteins 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 1
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 description 1
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 1
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 1
- 102100037680 Fibroblast growth factor 8 Human genes 0.000 description 1
- 102100037665 Fibroblast growth factor 9 Human genes 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000917237 Homo sapiens Fibroblast growth factor 10 Proteins 0.000 description 1
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 1
- 101001060261 Homo sapiens Fibroblast growth factor 7 Proteins 0.000 description 1
- 101001027382 Homo sapiens Fibroblast growth factor 8 Proteins 0.000 description 1
- 101001027380 Homo sapiens Fibroblast growth factor 9 Proteins 0.000 description 1
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 description 1
- 101000804792 Homo sapiens Protein Wnt-5a Proteins 0.000 description 1
- 101001086862 Homo sapiens Pulmonary surfactant-associated protein B Proteins 0.000 description 1
- 241000701149 Human adenovirus 1 Species 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 108091058560 IL8 Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 101800003050 Interleukin-16 Proteins 0.000 description 1
- 102000049772 Interleukin-16 Human genes 0.000 description 1
- 102100033461 Interleukin-17A Human genes 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 1
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028311 Muscle hypertrophy Diseases 0.000 description 1
- 108050003475 Neuregulin Proteins 0.000 description 1
- 102000014413 Neuregulin Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108090000630 Oncostatin M Proteins 0.000 description 1
- 102100031942 Oncostatin-M Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100032617 Pulmonary surfactant-associated protein B Human genes 0.000 description 1
- 101150040459 RAS gene Proteins 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108700025695 Suppressor Genes Proteins 0.000 description 1
- 108091005735 TGF-beta receptors Proteins 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 241001648319 Toronia toru Species 0.000 description 1
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000001400 Tryptase Human genes 0.000 description 1
- 108060005989 Tryptase Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102000043366 Wnt-5a Human genes 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 208000030270 breast disease Diseases 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000000512 collagen gel Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000002508 compound effect Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010226 confocal imaging Methods 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 230000008378 epithelial damage Effects 0.000 description 1
- 210000002782 epithelial mesenchymal cell Anatomy 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000011124 ex vivo culture Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 244000038280 herbivores Species 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000003963 intermediate filament Anatomy 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 230000007040 lung development Effects 0.000 description 1
- 230000032646 lung growth Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 208000011645 metastatic carcinoma Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000005486 microgravity Effects 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000012042 muscle hypertrophy Effects 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 235000020912 omnivore Nutrition 0.000 description 1
- 244000054334 omnivore Species 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001855 preneoplastic effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000009283 reversible contraction Effects 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000004085 squamous epithelial cell Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000005619 thermoelectricity Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0688—Cells from the lungs or the respiratory tract
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/02—Atmosphere, e.g. low oxygen conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1323—Adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/28—Vascular endothelial cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/04—Screening or testing on artificial tissues
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HUP0900819 | 2009-05-05 | ||
| HU0900819A HUP0900819A2 (en) | 2009-05-05 | 2009-05-05 | Lung tissue culture |
| PCT/IB2010/051978 WO2010128464A1 (fr) | 2009-05-05 | 2010-05-05 | Modèle de tissu pulmonaire |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102369277A CN102369277A (zh) | 2012-03-07 |
| CN102369277B true CN102369277B (zh) | 2014-12-17 |
Family
ID=89989476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201080020612.7A Expired - Fee Related CN102369277B (zh) | 2009-05-05 | 2010-05-05 | 肺组织模型 |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JP2013504303A (fr) |
| CN (1) | CN102369277B (fr) |
| AU (1) | AU2010244121B2 (fr) |
| CA (1) | CA2760768C (fr) |
| HU (1) | HUP0900819A2 (fr) |
| SG (1) | SG175425A1 (fr) |
| WO (1) | WO2010128464A1 (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE029316T2 (en) | 2010-11-04 | 2017-03-28 | Univ Of Pecs | Tüdõszövetmodell |
| JP5778412B2 (ja) * | 2010-11-29 | 2015-09-16 | 花王株式会社 | Ｃｇｒｐ応答調節剤の評価又は選択方法 |
| TWI438145B (zh) * | 2011-12-08 | 2014-05-21 | 中原大學 | 連續式產氫裝置及其方法 |
| US20140099709A1 (en) * | 2012-06-19 | 2014-04-10 | Organovo, Inc. | Engineered three-dimensional connective tissue constructs and methods of making the same |
| JP6463275B2 (ja) * | 2013-01-08 | 2019-01-30 | イエール ユニバーシティ | ヒトおよび大型哺乳動物の肺のバイオリアクター |
| WO2015061372A1 (fr) | 2013-10-21 | 2015-04-30 | Hemoshear, Llc | Modèle in vitro pour micro-environnement tumoral |
| CN104316661B (zh) * | 2014-10-08 | 2016-03-23 | 清华大学 | 用于生物毒性检测的肺组织模型及生物毒性检测方法 |
| CA2972226A1 (fr) * | 2014-12-24 | 2016-06-30 | Ube Industries, Ltd. | Fluide de surnageant de culture de cellules derive de tissu pulmonaire |
| US20190128870A1 (en) * | 2016-04-04 | 2019-05-02 | Humeltis | Diagnostic Methods For Patient Specific Therapeutic Decision Making In Cancer Care |
| CN106754669B (zh) * | 2016-11-23 | 2020-04-17 | 河海大学常州校区 | 基于反应-扩散模型的多细胞结构的制备方法及制备系统 |
| CN107267439A (zh) * | 2017-05-16 | 2017-10-20 | 苏州大学 | 三维肺微组织模型的构建方法及应用 |
| CN108660076A (zh) * | 2018-05-21 | 2018-10-16 | 中国科学院苏州生物医学工程技术研究所 | 一种仿真肺芯片模型 |
| CN109161531A (zh) * | 2018-10-16 | 2019-01-08 | 首都医科大学附属北京胸科医院 | 一种基于类器官技术个体化肺癌原代细胞培养的方法 |
| GB202005154D0 (en) * | 2020-04-07 | 2020-05-20 | Univ Of Hertfordshire Higher Education Corporation | Method and model |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080112890A1 (en) * | 2006-10-11 | 2008-05-15 | Lelkes Peter I | Fetal pulmonary cells and uses thereof |
| WO2007146267A3 (fr) * | 2006-06-15 | 2008-06-05 | Vaxdesign Corp | Incorporation d'un modèle de maladie dans un système immunitaire artificiel (sia) |
| WO2008100555A2 (fr) * | 2007-02-14 | 2008-08-21 | Drexel University | Construction de tissu pulmonaire de synthèse pour le dépistage de toxicité et la découverte de médicament à efficacité élevée |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6828111B2 (en) * | 2000-01-13 | 2004-12-07 | Wayne State University | Three-dimensional in vitro model of human preneoplastic breast disease |
| WO2003010302A1 (fr) * | 2001-07-26 | 2003-02-06 | Kazunori Kataoka | Construction cellulaire cultivee contenant des spheroides de cellules animales cultivees et utilisation correspondante |
| WO2007083504A1 (fr) * | 2003-08-01 | 2007-07-26 | Norimasa Nakamura | Tissu synthétique en 3d auto-organisé sans échafaudage |
-
2009
- 2009-05-05 HU HU0900819A patent/HUP0900819A2/hu unknown
-
2010
- 2010-05-05 AU AU2010244121A patent/AU2010244121B2/en not_active Ceased
- 2010-05-05 CN CN201080020612.7A patent/CN102369277B/zh not_active Expired - Fee Related
- 2010-05-05 WO PCT/IB2010/051978 patent/WO2010128464A1/fr active Application Filing
- 2010-05-05 JP JP2012509145A patent/JP2013504303A/ja active Pending
- 2010-05-05 SG SG2011080223A patent/SG175425A1/en unknown
- 2010-05-05 CA CA2760768A patent/CA2760768C/fr active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007146267A3 (fr) * | 2006-06-15 | 2008-06-05 | Vaxdesign Corp | Incorporation d'un modèle de maladie dans un système immunitaire artificiel (sia) |
| US20080112890A1 (en) * | 2006-10-11 | 2008-05-15 | Lelkes Peter I | Fetal pulmonary cells and uses thereof |
| WO2008100555A2 (fr) * | 2007-02-14 | 2008-08-21 | Drexel University | Construction de tissu pulmonaire de synthèse pour le dépistage de toxicité et la découverte de médicament à efficacité élevée |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010128464A1 (fr) | 2010-11-11 |
| SG175425A1 (en) | 2011-12-29 |
| CN102369277A (zh) | 2012-03-07 |
| AU2010244121B2 (en) | 2015-07-16 |
| HUP0900819A2 (en) | 2011-01-28 |
| JP2013504303A (ja) | 2013-02-07 |
| CA2760768C (fr) | 2019-10-29 |
| CA2760768A1 (fr) | 2010-11-11 |
| AU2010244121A1 (en) | 2011-12-15 |
| HU0900819D0 (en) | 2010-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102369277B (zh) | 肺组织模型 | |
| Szot et al. | 3D in vitro bioengineered tumors based on collagen I hydrogels | |
| Miserocchi et al. | Management and potentialities of primary cancer cultures in preclinical and translational studies | |
| Hellström et al. | Bioengineered uterine tissue supports pregnancy in a rat model | |
| TWI470081B (zh) | 肺組織模型 | |
| Kim | Three-dimensional tissue culture models in cancer biology | |
| EP3124600B1 (fr) | Rocédé de fabrication d'un condensé cellulaire dans l'objectif de son organisation automatique | |
| Li et al. | Generation of offspring-producing 3D ovarian organoids derived from female germline stem cells and their application in toxicological detection | |
| US20150284689A1 (en) | Strategy for engineering various 3d tissues, organoids and vasculature | |
| US20240336898A1 (en) | Formation of three-dimensional organ from pluripotent stem cells, method for generating cell condensate for self-organization | |
| CN111876371A (zh) | 心脏细胞培养材料 | |
| Nishikawa et al. | Migration and differentiation of transplanted enteric neural crest-derived cells in murine model of Hirschsprung’s disease | |
| CN116024158A (zh) | 子宫内膜类器官体外构建母胎界面的3d模型制备方法 | |
| CN102858956B (zh) | 血管生成的调节 | |
| JP5522340B2 (ja) | 胎生肝細胞のスフェロイドを含む培養細胞構築物 | |
| Miles et al. | In vitro porcine blastocyst development in three‐dimensional alginate hydrogels | |
| EP3684915A1 (fr) | Fabrication d'un système de plateforme biomimétique et procédés d'utilisation | |
| Deng et al. | Organ-on-a-chip: future of female reproductive pathophysiological models | |
| Chaji | Bioprinting of three-dimensional models to evaluate adipocyte breast cancer cell interactions and migration | |
| Shariatzadeh et al. | Stiffness of cell micro-environment guides long term cell growth in cell seeded collagen microspheres | |
| US20220072051A1 (en) | Prophylactic and/or therapeutic agent for diseases accompanied by fibrosis | |
| Sharma et al. | Do current bladder smooth muscle cell isolation procedures result in a homogeneous cell population? Implications for bladder tissue engineering | |
| Mecca et al. | The Limitations of Testicular Organoids: Are They Truly as Promising as We Believe? | |
| Cui | Advancements in testicular organoid research: insights for fertility preservation | |
| Yao et al. | Organoids: development and applications in disease models, drug discovery, precision medicine, and regenerative medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141217 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |